STD DIAGNOSTIC DEVELOPMENT GROUP (GONORRHEA)

Information

  • Research Project
  • 2076325
  • ApplicationId
    2076325
  • Core Project Number
    U01AI039226
  • Full Project Number
    1U01AI039226-01
  • Serial Number
    39226
  • FOA Number
    RFA-AI-95-01
  • Sub Project Id
  • Project Start Date
    9/30/1995 - 28 years ago
  • Project End Date
    8/31/1999 - 25 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1995 - 28 years ago
  • Budget End Date
    8/31/1996 - 28 years ago
  • Fiscal Year
    1995
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/29/1995 - 28 years ago
Organizations

STD DIAGNOSTIC DEVELOPMENT GROUP (GONORRHEA)

Current methodologies for diagnosing infection with Neisseria gonorrhoea require specimens that are obtained by invasive means: urethral swabs from men and cervical swabs from women. These specimens are usually cultured onto Thayer-Martin media; alternatively a variety of other methods can be employed to diagnose gonorrhea, but none is as sensitive as culture. The objective of this proposal is to create an inexpensive, rapid, simple and non-invasive immunologic test for gonorrhea. It must be as sensitive as culture and applicable for use in developing countries. The project will be accomplished through 3 specific aims: (l) to optimize an already existing prototype assay called the HygEIA GC Test to use with non- invasive specimens, and to convert this ELISA format to an immunochromatographic (ICT) format with a membrane read-out. Initially, the assay will be developed using two existing antibodies, one directed against the H8 antigen (a current component of the HygEIA GC Test) and a gonococcal anti-lipooligosaccliaride antibody that reacts broadly with N. gonorrhoea; (2) to create polyclonal antibody libraries using a molecular cloning system that produces antibodies that recognize multiple epitopes on gonococcal surfaces exclusively; simultaneously these libraries will be immortalized and can be utilized time and again to produce, antibodies with reproducible specificities and; (3) to use patients at risk for gonorrhea to test prototype formats. Through overlapping strategies, beginning with a prototype that already functions, it is anticipated that a final product will emerge.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    U01
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SRC
  • Study Section Name
  • Organization Name
    BINAX, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    PORTLAND
  • Organization State
    ME
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    04103
  • Organization District
    UNITED STATES